BioSpace News Archive

Florida Blue announced that it is making an initial investment of $2 million to address urgent health and safety needs in communities across Florida, the company’s latest response to the COVID-19 public health crisis.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced the results from field tests conducted in the 2019 growing season in the United States and Canada.

Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, and SciClone Pharmaceuticals International Ltd., (“SciClone”) today announced that they have entered into a licensing agreement for PEN-866,

High performance computing resources immediately available at no cost to engineers, scientists, and researchers fighting the novel coronavirus

In response to the Wallstreet Journal’s recent article, “Whether You’re Tested for Coronavirus Depends on Where You Live,” Linked Enterprises got together with industry experts to provide Mobile Testing/Collection Facilities.

Fred Hutchinson Cancer Research Center remains open and committed to our mission of curing cancer and other diseases. We are collectively focusing on how to ensure our researchers and their respective labs are safe and in the best position to manage COVID-19 related disruptions—particularly those we can’t necessarily predict.

Bio-Rad Laboratories, Inc. announced that in two studies published this month, ahead of peer-review, researchers in China reported that Bio-Rad’s QX200 Droplet Digital PCR System showed superior sensitivity and precision for clinical detection of SARS-CoV-2 compared to existing test methods that are performed using qPCR.

OncoOne today announced the close of a EUR 13 million Series A financing round, marking its industry debut. OncoOne will develop several drug modalities to target oxidized macrophage migration inhibitory factor (oxMIF), an isoform of macrophage migration inhibitory factor (MIF) and an exciting new drug target in solid tumor cancer indications

ERYTECH Pharma announced that it had filed its 2019 Universal Registration Document for the year ended December 31, 2019, including the management report and the annual financial report with the “Autorité des Marchés Financiers ” and its Annual Report on Form 20-F for the year ended December 31, 2019 with the U.S.

Immutep Limited, is pleased to report that it has been informed its Chinese partner, EOC Pharma, has completed patient recruitment for the ongoing EOC202A1101 study being conducted in China.